How Synthetic Peptides Are Expanding Opportunities in Biotechnology Research
In 2020, a machine at MIT built a protein chain 164 amino acids long. It ran 327 chemical reactions one after another and finished the job in a matter of hours. To see why that impressed chemists, it helps to know that assembling such chains step by step had been getting unreliable beyond about fifty amino acids, so anyone who needed something longer had to find another route.
The achievement was part of a much broader change. Thirty years ago, making a peptide with an exact, chosen sequence of amino acids was specialist work. Today a biologist can describe the sequence they want, order it from a supplier and have it on the bench within a few weeks. That shift has widened the range of questions a laboratory can realistically afford to ask.
Why Synthetic Peptides Matter in Modern Research
Imagine a receptor on the surface of a cell that responds strongly to one hormone but almost ignores another one that looks very similar. Which amino acids account for the difference?
That question is hard to answer using protein extracted from tissue, because no two batches come out quite the same, and it is not always obvious whether a change in the results reflects real biology or simply a difference between preparations. A synthetic peptide gives far more control. Researchers can order the original sequence along with a set of versions in which a single amino acid has been swapped, test them side by side and watch which swap changes the behaviour.
Short synthetic sequences are also useful for working out how two proteins find and grip each other. By making separate pieces of a larger protein and testing each one, researchers can narrow down which stretch of the molecule does most of the binding.
There is a more down-to-earth benefit as well. When the composition and purity of a peptide have been measured and documented, there is one fewer unknown to worry about if an experiment produces a strange result. The material can still cause problems, but at least the laboratory knows what it started with.
New Opportunities Across Biotechnology
Molecular and Cellular Biology
Proteins constantly bind to one another, and those contacts govern much of what happens inside a cell. Interfering with such interactions is difficult for a geometric reason. Conventional small molecules attach to a protein where its surface has a deep indentation, a pocket of sorts, which the molecule fits into snugly and is held in place by. Protein–protein contacts usually have no such indentations, since the surfaces that meet are broad and almost flat, leaving a small molecule nothing to grip.
Stapled peptides take a different route. Inside a folded protein, a short stretch of the chain is often coiled into an alpha helix, and it is that helix which presses against the binding partner. Cut the stretch out and synthesise it on its own, and the helix unwinds, taking the ability to bind with it. To prevent this, chemists join two side chains with a short hydrocarbon bridge, the “staple”, which holds the coil in the shape it needs.
ATSP-7041 shows what this is worth. It was designed to interact with MDM2 and MDMX, two proteins that keep the tumour suppressor p53 in check. Without the staple, only about 11% of the sequence holds its spiral form, while with it almost 70% does. Comparing the two versions lets researchers see how much of the binding depends on shape alone in experiments with living cells.
Metabolic Research
Samuel Gellman’s group at the University of Wisconsin tried something less obvious. Most teams modify the side chains, the chemical groups that stick out from the chain and do the recognising, whereas these researchers changed the chain itself.
Natural peptides are built from α-amino acids. The group replaced some of them in GLP-1, a hormone involved in blood sugar control, with β-amino acids, which carry one extra carbon atom in the backbone. The resulting analogues still activated the GLP-1 receptor, but they did so unevenly. A receptor can set off more than one internal response, and these modified peptides shifted the balance between two of them, G protein signalling and β-arrestin recruitment.
The experiments were carried out in cultured cells carrying the human receptor. They tell us something about how receptors work, not about what happens in patients.
Biomaterials and Tissue Engineering
RADA16-I is a peptide only sixteen amino acids long, with a curious habit. Place it in a salt solution and the molecules line up into fine fibres that tangle together into a soft, water-filled gel.
That gel is useful because cells can be grown inside it rather than on a flat dish, and because its composition is fully known. The usual alternatives are extracted from animal tissue and vary from batch to batch. In one line of research, ovarian cancer cells grown in RADA16-based gels clumped into aggregates and rounded spheroids, and they responded to the chemotherapy drugs cisplatin and paclitaxel differently from the same cells grown flat.
That difference is exactly the point. A cell lying on plastic is not in the same situation as a cell surrounded on all sides by a supporting mesh, and peptide gels let researchers study that gap under controlled conditions.
All of these examples come from laboratory systems. None of them establishes an effect in people.
How Advances in Peptide Synthesis Support Research
Bruce Merrifield worked out the underlying method in 1963. He anchored the first amino acid to a small solid bead and added the rest one at a time, which meant that leftover chemicals could be rinsed away between steps instead of being separated out by hand. The approach saved an enormous amount of labour and later earned him a Nobel Prize.
The principle has not changed since, but the machinery around it has. Automated instruments, including systems that pump reagents continuously past the bead, have cut synthesis times and brought awkward sequences within reach.
Making the peptide is only half the work, though. A laboratory also has to confirm that the vial contains what the label claims.
Two techniques do most of that job. High-performance liquid chromatography separates the intended molecule from shorter fragments and other by-products left over from the synthesis, which shows how pure the sample is. Mass spectrometry weighs the molecules present, which helps confirm that the sequence is the right one. Each answers a different question, and neither is sufficient by itself.
Without both, a surprising experimental result becomes much harder to interpret, because the explanation might lie in the biology, in the assay, or simply in the contents of the vial.
Access to Research Materials and the Role of Specialized Suppliers
Very few laboratories make all their own peptides. Running a synthesis setup means equipment, trained staff and analytical instruments, which is hard to justify for a group that needs a handful of sequences a year.
Most buy from outside instead, which turns the problem into a different one. Does the laboratory receive enough information to judge what it has bought?
Documentation tied to the specific batch helps a great deal here. Figures for identity and purity measured on that particular lot, rather than on an earlier representative sample, give a much clearer picture, even though no certificate rules out every possible source of variation.
Specialised suppliers such as Purita Peptides provide research peptides together with batch-specific analytical documentation and ship worldwide. For smaller institutions without synthesis facilities of their own, that kind of access can decide whether a planned experiment goes ahead or gets shelved.
What Comes Next for Peptide-Based Biotechnology?
So far this has been about making a peptide and confirming its quality. Everything starts with a different question, though, which is what sequence is worth making in the first place. That question was answered by hand for a long time, working from natural proteins and accumulated experience, and it is where the work is now changing fastest. Generative models trained on protein structures propose sequences intended to bind a particular molecular target, leaving the laboratory to synthesise those candidates and test them experimentally. Trial and error has not become any less common, since many of the proposed sequences behave quite differently from the prediction and every one of them has to be verified again at the bench. The gain lies in speed, because when design and synthesis each take weeks rather than months, a team can work through far more candidates in the same period than it could with the older, largely manual approach.
A second direction is developing alongside this one, in the form of peptide biomaterials. Experimental scaffolds that once gave cells nothing more than physical support now increasingly carry specific chemical signals, meaning sites that a cell can anchor to and motifs that prompt it to migrate or change its behaviour.
References
- Hartrampf N, et al. Synthesis of proteins by automated flow chemistry. Science. 2020;368(6494):980–987. DOI: 10.1126/science.abb2491
- Robertson NS, Jamieson AG. Regulation of protein–protein interactions using stapled peptides. Reports in Organic Chemistry. 2015;5:65–74. DOI: 10.2147/ROC.S68161
- Robertson NS, Spring DR. Using peptidomimetics and constrained peptides as valuable tools for inhibiting protein–protein interactions. Molecules. 2018;23(4):959. DOI: 10.3390/molecules23040959
- Hager MV, Johnson LM, Wootten D, Sexton PM, Gellman SH. β-Arrestin-biased agonists of the GLP-1 receptor from β-amino acid residue incorporation into GLP-1 analogues. J Am Chem Soc. 2016;138(45):14970–14979. PMC5207657
- Three-dimensional culture of ovarian cancer cells in RADA16-I peptide nanofibre hydrogel. J Nanobiotechnology. 2020;18:88. DOI: 10.1186/s12951-020-00646-x
